Novartis AG 2009 Annual Results Summary
Business Context and Reporting Period
This Form 6-K, dated January 26, 2010, reports the full-year 2009 financial results for Novartis AG, a global healthcare company headquartered in Basel, Switzerland. The reporting period covers the fiscal year ended December 31, 2009. The filing highlights record results driven by innovative product launches, the successful delivery of H1N1 pandemic vaccines, and the completion of a CEO succession plan with Joe Jimenez appointed as the new CEO effective February 1, 2010.
Key Financial Metrics
| Metric | 2009 (USD) | 2008 (USD) | Change (USD) | Change (Local Currency) |
|---|---|---|---|---|
| Net Sales | $44.3 billion | $41.5 billion | +7% | +11% |
| Operating Income | $10.0 billion | $9.0 billion | +11% | N/A |
| Core Operating Income | $11.4 billion | $10.3 billion | +11% | N/A |
| Net Income | $8.5 billion | $8.2 billion | +4% | N/A |
| Core Net Income | $10.3 billion | $9.5 billion | +8% | N/A |
| Basic EPS | $3.70 | $3.59 | +3% | N/A |
| Core Basic EPS | $4.50 | $4.18 | +8% | N/A |
| Free Cash Flow (pre-dividends) | $9.4 billion | $7.6 billion | +24% | N/A |
| Operating Margin | 22.5% | 21.6% | +0.9 pts | N/A |
| Core Operating Margin | 25.8% | 25.0% | +0.8 pts | N/A |
Liquidity and Debt: Total assets rose to $95.6 billion. The company returned to a net liquidity position of $3.5 billion (up from net debt of $1.2 billion in 2008), supported by $17.4 billion in total liquidity. Financial debt totaled $14.0 billion, with a debt-to-equity ratio of 0.24:1.
Material Changes vs. Prior Period
- Revenue Growth: Net sales grew 7% in USD (11% in local currencies). Growth was driven by Pharmaceuticals (+12% lc), Vaccines and Diagnostics (+39% lc), and Sandoz (+5% lc). The stronger US dollar reduced reported USD growth by approximately 4 percentage points.
- Profitability: Core operating income grew 11% to $11.4 billion, outpacing sales growth due to productivity gains and business expansion. The core operating margin improved to 25.8%.
- Divisional Performance:
- Pharmaceuticals: Achieved industry-leading growth with recently launched products contributing $4.7 billion in sales. Oncology and Cardiovascular/Metabolism were top franchises.
- Vaccines and Diagnostics: Sales surged 39% in local currencies, primarily due to $1.0 billion in sales from H1N1 pandemic vaccines and adjuvants.
- Sandoz: Sales remained flat in USD (-1%) but grew 5% in local currencies, aided by the EBEWE Pharma acquisition.
- Exceptional Items: Net income growth (4%) was lower than core operating income growth due to Alcon-related financing costs and increased legal provisions (specifically a $318 million increase for Trileptal investigations).
Guidance, Outlook, and Risks
2010 Outlook: Management expects Group net sales to grow at a mid-single-digit rate in local currencies. Pharmaceuticals sales are expected to grow at a mid- to high-single-digit rate, though pricing pressures in the US, Turkey, and Japan, as well as generic competition for Diovan, pose challenges. Vaccines and Diagnostics sales are expected to be well below 2009 levels as H1N1 demand normalizes.
Strategic Priorities:
- Alcon Acquisition: Novartis announced the exercise of its option to acquire the remaining 52% stake in Alcon from Nestlé for $28.1 billion, followed by a proposed all-share merger for the remaining 23% minority stake. This aims to create a global eye-care leader.
- Leadership: Joe Jimenez assumes the CEO role on February 1, 2010, with Dr. Daniel Vasella remaining as Chairman. The Executive Committee was reduced from 12 to 9 members.
- Productivity: The "Forward" productivity program exceeded its savings goal by nearly 50% a year ahead of schedule.
Risks and Contingencies:
- Legal Proceedings: Significant ongoing investigations include US federal inquiries into marketing practices for Trileptal, Diovan, Exforge, Sandostatin, Tekturna, and Zelnorm. A $397 million provision was set aside for Trileptal-related civil and criminal claims.
- Patent Litigation: Ongoing disputes regarding contact lens patents (CIBA Vision vs. Johnson & Johnson) and Zometa/Aredia osteonecrosis claims.
- Regulatory: Potential delays or rejections for new product approvals (e.g., Gilenia, Menveo) and pricing pressures from healthcare reforms.
Investor Verification Checklist
- Alcon Merger Status: Verify the regulatory approval timeline and final terms for the full acquisition and merger of Alcon, including the exchange ratio for minority shareholders.
- Legal Provisions: Monitor the resolution of the Trileptal and other US federal marketing investigations to assess if the $397 million provision is sufficient or if further charges are required.
- H1N1 Vaccine Normalization: Confirm the magnitude of the sales decline in the Vaccines and Diagnostics division in 2010 compared to the exceptional 2009 pandemic volumes.
- Generic Competition: Track the market impact of generic entry for Diovan in Europe (2011) and the US (2012), and the immediate impact of therapeutic-class generic competition in 2010.
- CEO Transition: Assess the early execution of strategic priorities under the new CEO, Joe Jimenez, particularly regarding the integration of Alcon and the simplified organizational structure.